Multiple Delivery of siRNA against Endoglin into Murine Mammary Adenocarcinoma Prevents Angiogenesis and Delays Tumor Growth

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Dolinsek, Tanja ^a   Markelc, Bostjan ^a   Sersa, Gregor ^a   Coer, Andrej ^b   Stimac, Monika ^a   Lavrencak, Jaka ^a   Brozic, Andreja ^a   Kranjc, Simona ^a   Cemazar, Maja ^a,b  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL MOUSE; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPORATION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR BURDEN;

EID: 84874625300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058723     Document Type: Article

References (49)

1. Orlova VV, Liu Z, Goumans MJ, ten Dijke P, (2011) Controllingangiogenesis by two unique TGF-beta type I receptor signaling pathways. HistolHistopathol 26: 1219-1230.
2. Thurston G, Kitajewski J, (2008) VEGFand Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 99: 1204-1209.
3. ten Dijke P, Goumans MJ, Pardali E, (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89.
4. Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ, et al. (2012) Structural and functional insights into endoglin ligandrecognition and binding. PLoS One 7: e29948.
5. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, et al. (1995) Up-regulationof endoglin on vascular endothelial cells in human solid tumors: implicationsfor diagnosis and therapy. Clin Cancer Res 1: 1623-1634.
6. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, et al. (2008) Endoglin (CD105): a marker of tumor vasculature and potentialtarget for therapy. Clin Cancer Res 14: 1931-1937.
7. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, et al. (1999) Elevatedexpression of endoglin, a component of the TGF-beta-receptorcomplex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81: 568-572.
8. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R, (2000) Imagingof tumour neovasculature by targeting the TGF-beta binding receptorendoglin. Eur J Cancer 36: 675-681.
9. Costello B, Chenggang LG, Duff S, Butterworth D, Khan A, et al. (2004) Perfusion of Tc-99(m)-labeled CD105 Mab into kidneysfrom patients with renal carcinoma suggests that CD105 is a promising vasculartarget. International Journal of Cancer 109: 436-441.
10. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, et al. (2000) Endoglin is a suitable target for efficient imagingof solid tumors: in vivo evidence in a canine mammary carcinoma model. ClinCancer Res 6: 2037-2043.
11. Zhang Y, Yang Y, Hong H, Cai W, (2011) Multimodality molecular imaging ofCD105 (Endoglin) expression. Int J Clin Exp Med 4: 32-42.
12. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, et al. (1999) Breastcarcinoma: vascular density determined using CD105 antibody correlateswith tumor prognosis. Cancer Res 59: 856-861.
13. Kyzas PA, Agnantis NJ, Stefanou D, (2006) Endoglin (CD105) as a prognostic factor inhead and neck squamous cell carcinoma. Virchows Archiv 448: 768-775.
14. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, et al. (2001) Evaluationof angiogenesis in non-small cell lung cancer: comparison betweenanti-CD34 antibody and anti-CD105 antibody. ClinCancer Res 7: 3410-3415.
15. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Kontermann RE, Sheikholislami F, (2009) Cell selection and characterization of a novel humanendothelial cell specific nanobody. Mol Immunol 46: 1814-1823.
16. Maier JA, Delia D, Thorpe PE, Gasparini G, (1997) Invitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470)and the anti-endoglin antibody TEC-11. AnticancerDrugs 8: 238-244.
17. She X, Matsuno F, Harada N, Tsai H, Seon BK, (2004) Synergybetween anti-endoglin (CD105) monoclonal antibodies and TGF-betain suppression of growth of human endothelial cells. Int J Cancer 108: 251-257.
18. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, et al. (1999) Inductionof lasting complete regression of preformed distinct solid tumors by targetingthe tumor vasculature using two new anti-endoglin monoclonal antibodies. ClinCancer Res 5: 371-382.
19. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M, (1997) Long-lastingcomplete inhibition of human solid tumors in SCID mice by targeting endothelialcells of tumor vasculature with antihuman endoglin immunotoxin. ClinCancer Res 3: 1031-1044.
20. Tabata M, Kondo M, Haruta Y, Seon BK, (1999) Antiangiogenicradioimmunotherapy of human solid tumors in SCID mice using (125)I-labeledanti-endoglin monoclonal antibodies. Int J Cancer 82: 737-742.
21. Takahashi N, Haba A, Matsuno F, Seon BK, (2001) Antiangiogenictherapy of established tumors in human skin/severe combined immunodeficiencymouse chimeras by anti-endoglin (CD105) monoclonal antibodies,and synergy between anti-endoglin antibody and cyclophosphamide. CancerRes 61: 7846-7854.
22. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, et al. (2008) Anti-tumoractivity of an anti-endoglin monoclonal antibody is enhanced in immunocompetentmice. Int J Cancer 122: 2266-2273.
23. Tsujie M, Uneda S, Tsai H, Seon BK, (2006) Effectiveanti-angiogenic therapy of established tumors in mice by naked anti-humanendoglin (CD105) antibody: differences in growth rate andtherapeutic response between tumors growing at different sites. Int J Oncol 29: 1087-1094.
24. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, et al. (2009) Anti-endoglinmonoclonal antibodies are effective for suppressing metastasis and the primarytumors by targeting tumor vasculature. Int J Cancer 125: 1446-1453.
25. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, et al. (2004) Endoglin promotes endothelial cell proliferation andTGF-beta/ALK1 signal transduction. EMBO J 23: 4018-4028.
26. Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, et al. (2002) Effective gene transfer to solid tumors using different nonviralgene delivery techniques: electroporation, liposomes, and integrin-targetedvector. Cancer Gene Ther 9: 399-406.
27. Duff SE, Li C, Garland JM, Kumar S, (2003) CD105is important for angiogenesis: evidence and potential applications. FASEB J 17: 984-992.
28. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, et al. (1999) Defectiveangiogenesis in mice lacking endoglin. Science 284: 1534-1537.
29. Arnaoutova I, George J, Kleinman HK, Benton G, (2009) Theendothelial cell tube formation assay on basement membrane turns 20:state of the science and the art. Angiogenesis 12: 267-274.
30. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, et al. (2000) CD105antagonizes the inhibitory signaling of transforming growth factor beta1 onhuman vascular endothelial cells. FASEB J 14: 55-64.
31. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J, (2006) Electrically-assistednucleic acids delivery to tissues in vivo: where do we stand? CurrPharm Des 12: 3817-3825.
32. Golzio M, Mazzolini L, Paganin-Gioanni A, Teissie J, (2009) Targetedgene silencing into solid tumors with electrically mediated siRNA delivery. MethodsMol Biol 555: 15-27.
33. Kimelman-Bleich N, Pelled G, Zilberman Y, Kallai I, Mizrahi O, et al. (2011) Targetedgene-and-host progenitor cell therapy for nonunion bone fracturerepair. Mol Ther 19: 53-59.
34. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, et al. (2008) Phase I trial of interleukin-12 plasmid electroporationin patients with metastatic melanoma. Journal of ClinicalOncology 26: 5896-5903.
35. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, et al. (2011) Electrochemotherapy:a new technological approach in treatment of metastases in the liver. TechnolCancer Res Treat 10: 475-485.
36. Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, et al. (2011) Electrogenetherapy with interleukin-12 in canine mast cell tumors. Radiologyand Oncology 45: 31-39.
37. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, et al. (2008) Electrochemotherapyin treatment of tumours. Eur J Surg Oncol 34: 232-240.
38. Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, et al. (2007) Invivo gene silencing in solid tumors by targeted electrically mediated siRNAdelivery. Gene Ther 14: 752-759.
39. Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, et al. (2008) Invivo silencing of a molecular target by short interfering RNA electroporation:tumor vascularization correlates to delivery efficiency. MolCancer Ther 7: 211-221.
40. Vader P, vander Meel R, Symons MH, Fens MH, Pieters E, et al. (2011) Examining the role of Rac1 in tumorangiogenesis and growth: a clinically relevant RNAi-mediatedapproach. Angiogenesis 14: 457-466.
41. White PJ, (2008) Barriers to successful delivery of short interferingRNA after systemic administration. Clin Exp Pharmacol Physiol 35: 1371-1376.
42. Maitland ML, Lou XJ, Ramirez J, Desai AA, Berlin DS, et al. (2010) Vascular endothelial growth factorpathway. Pharmacogenet Genomics 20: 346-349.
43. Pardali E, ten Dijke P, (2012) TGFbeta Signaling and Cardiovascular Diseases. InternationalJournal of Biological Sciences 8: 195-213.
44. Yamamoto T, Kozawa O, Tanabe K, Akamatsu S, Matsuno H, et al. (2001) Involvementof p38 MAP kinase in TGF-beta-stimulated VEGF synthesis in aorticsmooth muscle cells. J Cell Biochem 82: 591-598.
45. Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, et al. (2011) Intracranialhemorrhage in patients treated with bevacizumab: report of two cases. World J Gastroenterol 17: 4440-4444.
46. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T, (2012) Sunitinib-inducednephrotic syndrome and irreversible renal dysfunction. ClinExp Nephrol 16: 310-315.
47. Nanni P, deGiovanni C, Lollini PL, Nicoletti G, Prodi G, (1983) TS/A: a new metastasizing cell line from a BALB/cspontaneous mammary adenocarcinoma. Clin Exp Metastasis 1: 373-380.
48. Vo E, Hanjaya-Putra D, Zha Y, Kusuma S, Gerecht S, (2010) Smooth-muscle-likecells derived from human embryonic stem cells support and augment cord-likestructures in vitro. Stem Cell Rev 6: 237-247.
49. Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I, (2005) Robustquantification of in vitro angiogenesis through image analysis. IEEETrans Med Imaging 24: 549-553.